Skip to main content

IL-23

PSA2L.jpg
At EULAR 2022, I have been looking at topics and presentations in psoriatic arthritis (PsA).  How do PsA patients do on csDMARDs and is the time to switch or escalate to biologics the same as for RA…
RT @doctorRBC: In vitro study shows Upadacitinib inhibits enthesis T cell derived TNFa and IL-17A, disrupting the promin

Robert B Chao, MD doctorRBC

1 month ago
In vitro study shows Upadacitinib inhibits enthesis T cell derived TNFa and IL-17A, disrupting the prominent IL-23/IL-17/TNFa axis driving SpA. @RheumNow #EULAR2022 ABST#POS0331 https://t.co/pNL3Zlgmt7
RT @RichardPAConway: Kohm et al. Efficacy of IL12/23i ustekinumab independent of MTX in PsA. No additive benefit of MTX

Richard Conway RichardPAConway

1 month ago
Kohm et al. Efficacy of IL12/23i ustekinumab independent of MTX in PsA. No additive benefit of MTX on joint, skin, QoL, function @RheumNow #EULAR2022 POS1059
RT @RichardPAConway: Magrey et al. IL23i Risankizumab improves enthesitis in PsA @RheumNow #EULAR2022 POS1057 https://t.

Richard Conway RichardPAConway

1 month ago
Magrey et al. IL23i Risankizumab improves enthesitis in PsA @RheumNow #EULAR2022 POS1057 https://t.co/BjuYj6xUdZ
RT @RichardPAConway: Dr Coates @DrLauraCoates et al. Domains contributing to MDA achievement in guselkumab treated PsA.

Richard Conway RichardPAConway

1 month ago
Dr Coates @DrLauraCoates et al. Domains contributing to MDA achievement in guselkumab treated PsA. Physican assessed improved faster than patient assessed. Age, fatigue, BMI, baseline domain score determinants @RheumNow #EULAR2022 POS1067 https://t.co/vPsmeyPjzG
RT @RichardPAConway: Dr Nash @drpnash Baseline determinants of pain response in IL23i guselkumab. Gus improved pain by w

Richard Conway RichardPAConway

1 month ago
Dr Nash @drpnash Baseline determinants of pain response in IL23i guselkumab. Gus improved pain by week 2. Higher baseline pain, lower fatigue, lower TJC + predictors, NSAID use - predictor @RheumNow #EULAR2022 POS1070 https://t.co/4aNz9IQySj
RT @Janetbirdope: High markers at baseline of IL23 pathway better predict ACR20 response to #deucracitinib in #PsA #psor

Janet Pope Janetbirdope

1 month ago
High markers at baseline of IL23 pathway better predict ACR20 response to #deucracitinib in #PsA #psoriatic arthritis. Analysis of RCT @eular_org @RheumNow #POS0005 Good proof of concept of TYK2 efficacy https://t.co/yyH5niUEEU
RT @RichardPAConway: Kristensen et al. IL23i Risankizumab improves fatigue, health related quality of life, work product

Richard Conway RichardPAConway

1 month ago
Kristensen et al. IL23i Risankizumab improves fatigue, health related quality of life, work productivity in PsA. @RheumNow #EULAR2022 POS1042 https://t.co/fnoCZCpwNM
RT @RichardPAConway: Nash @drpnash et al. IL23i guselkumab improves pain in PsA. Good to see as it is a really important

Richard Conway RichardPAConway

1 month ago
Nash @drpnash et al. IL23i guselkumab improves pain in PsA. Good to see as it is a really important PRO, but there is still significant work to do, week 24 - 60% had <50% and 37% had <20% improvement in pain @RheumNow #EULAR2022 POS1044 https://t.co/H92r4leslT
×